Imunon, Inc. Payments to Acquire Available-for-sale Securities
Imunon, Inc. (IMNN) reported Payments to Acquire Available-for-sale Securities of $9.96 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2021-03-19
- Imunon, Inc. payments to acquire available-for-sale securities for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. payments to acquire available-for-sale securities for the quarter ending 2020-09-30 was $16.00K, a 99.74% decline year-over-year.
- Imunon, Inc. payments to acquire available-for-sale securities for the quarter ending 2020-06-30 was $360.00, a 99.98% decline year-over-year.
- Imunon, Inc. payments to acquire available-for-sale securities for the quarter ending 2020-03-31 was $9.94M, a 11.65% decline year-over-year.
- Imunon, Inc. payments to acquire available-for-sale securities for fiscal 2020 was $9.96M, a 58.22% decline from fiscal 2019.
- Imunon, Inc. payments to acquire available-for-sale securities for fiscal 2019 was $23.83M, a 40.39% increase from fiscal 2018.
- Imunon, Inc. payments to acquire available-for-sale securities for fiscal 2018 was $16.97M, a 33.29% increase from fiscal 2017.
- Imunon, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $12.73M, a 182.24% increase from fiscal 2016.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 6 month as first filed | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $16.00K derived: sum of 2 quarters · filed 2021-03-19 | $16.36K derived: sum of 3 quarters · filed 2021-03-19 | $9.96M 10-K · filed 2021-03-19 | ||
| 2020-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $16.36K derived: sum of 2 quarters · filed 2020-11-16 | $9.96M 10-Q · filed 2020-11-16 | $14.45M derived: sum of 4 quarters · filed 2021-03-19 | ||
| 2020-06-30 | $360.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $9.94M 10-Q · filed 2020-08-14 | $14.43M derived: sum of 3 quarters · filed 2021-03-19 | $20.49M derived: sum of 4 quarters · filed 2021-03-19 | ||
| 2020-03-31 | $9.94M 10-Q · filed 2020-05-15 | $14.43M derived: sum of 2 quarters · filed 2021-03-19 | $20.49M derived: sum of 3 quarters · filed 2021-03-19 | $22.52M derived: sum of 4 quarters · filed 2021-03-19 | ||
| 2019-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $10.55M derived: sum of 2 quarters · filed 2021-03-19 | $12.58M derived: sum of 3 quarters · filed 2021-03-19 | $23.83M 10-K · filed 2021-03-19 | ||
| 2019-09-30 | $6.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $8.09M derived: sum of 2 quarters · filed 2020-11-16 | $19.34M 10-Q · filed 2020-11-16 | $20.74M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $13.28M 10-Q · filed 2020-08-14 | $14.68M derived: sum of 3 quarters · filed 2020-08-14 | $24.54M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $11.25M 10-Q · filed 2020-05-15 | $12.65M derived: sum of 2 quarters · filed 2020-05-15 | $22.51M derived: sum of 3 quarters · filed 2020-05-15 | $22.52M derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $11.26M derived: sum of 2 quarters · filed 2020-03-25 | $11.26M derived: sum of 3 quarters · filed 2020-03-25 | $16.97M 10-K · filed 2020-03-25 | ||
| 2018-09-30 | $9.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $9.86M derived: sum of 2 quarters · filed 2019-11-14 | $15.57M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $1.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $5.71M 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | $5.71M 10-Q · filed 2019-05-15 | |||||
| 2017-12-31 | $12.73M 10-K · filed 2019-03-29 | |||||
| 2016-12-31 | -$3.34K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-27 | $2.35M derived: sum of 2 quarters · filed 2018-03-27 | $4.51M 10-K · filed 2018-03-27 | |||
| 2016-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $4.52M 10-Q · filed 2017-11-14 | ||||
| 2016-06-30 | $2.16M 10-Q · filed 2017-08-14 | |||||
| 2015-12-31 | -$3.86K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $5.59M derived: sum of 2 quarters · filed 2017-03-24 | $5.80M derived: sum of 3 quarters · filed 2017-03-24 | $21.07M 10-K · filed 2017-03-24 | ||
| 2015-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $5.80M derived: sum of 2 quarters · filed 2016-11-10 | $21.08M 10-Q · filed 2016-11-10 | $21.73M derived: sum of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | $210.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $15.49M 10-Q · filed 2016-08-15 | $16.14M derived: sum of 3 quarters · filed 2016-08-15 | $22.82M derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | $15.28M 10-Q · filed 2016-05-16 | $15.93M derived: sum of 2 quarters · filed 2016-05-16 | $22.61M derived: sum of 3 quarters · filed 2016-05-16 | $27.24M derived: sum of 4 quarters · filed 2016-05-16 | ||
| 2014-12-31 | $650.10K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $7.33M derived: sum of 2 quarters · filed 2016-03-30 | $11.96M derived: sum of 3 quarters · filed 2016-03-30 | $29.83M 10-K · filed 2016-03-30 | ||
| 2014-09-30 | $6.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $11.31M derived: sum of 2 quarters · filed 2015-11-05 | $29.18M 10-Q · filed 2015-11-05 | $52.91M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-06-30 | $4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $22.49M 10-Q · filed 2015-08-10 | $46.23M derived: sum of 3 quarters · filed 2016-03-30 | $48.82M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-03-31 | $17.86M 10-Q · filed 2015-05-11 | $41.60M derived: sum of 2 quarters · filed 2016-03-30 | $44.19M derived: sum of 3 quarters · filed 2016-03-30 | $63.94M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2013-12-31 | $23.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $26.33M derived: sum of 2 quarters · filed 2016-03-30 | $46.08M derived: sum of 3 quarters · filed 2016-03-30 | $66.32M 10-K · filed 2016-03-30 | $66.38M 10-K · filed 2014-03-13 | |
| 2013-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $22.34M derived: sum of 2 quarters · filed 2014-11-10 | $42.58M 10-Q · filed 2014-11-10 | $42.77M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-06-30 | $19.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $40.00M 10-Q · filed 2014-08-07 | $39.80M 10-Q · filed 2013-08-08 | $40.18M derived: sum of 3 quarters · filed 2015-03-12 | $45.02M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-03-31 | $20.25M 10-Q · filed 2014-05-08 | $20.43M derived: sum of 2 quarters · filed 2015-03-12 | $25.27M derived: sum of 3 quarters · filed 2015-03-12 | $26.33M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2012-12-31 | $180.70K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $5.03M derived: sum of 2 quarters · filed 2015-03-12 | $6.08M derived: sum of 3 quarters · filed 2015-03-12 | $16.39M 10-K · filed 2015-03-12 | $16.21M 10-K · filed 2013-03-18 | |
| 2012-09-30 | $4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $5.90M derived: sum of 2 quarters · filed 2013-11-12 | $16.21M 10-Q · filed 2013-11-12 | $16.46M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $11.37M 10-Q · filed 2013-08-08 | $11.61M derived: sum of 3 quarters · filed 2014-03-13 | $22.03M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-03-31 | $10.31M 10-Q · filed 2013-05-09 | $10.55M derived: sum of 2 quarters · filed 2014-03-13 | $20.97M derived: sum of 3 quarters · filed 2014-03-13 | $20.97M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2011-12-31 | $243.75K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $10.66M derived: sum of 2 quarters · filed 2014-03-13 | $10.66M derived: sum of 3 quarters · filed 2014-03-13 | $10.66M 10-K · filed 2014-03-13 | ||
| 2011-09-30 | $10.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $10.42M derived: sum of 2 quarters · filed 2012-11-09 | $10.42M 10-Q · filed 2012-11-09 | $10.66M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $0.00 10-Q · filed 2011-08-09 | $242.43K derived: sum of 3 quarters · filed 2013-03-18 | $352.80K derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-15 | $242.43K derived: sum of 2 quarters · filed 2013-03-18 | $352.80K derived: sum of 3 quarters · filed 2013-03-18 | |||
| 2010-12-31 | $242.43K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $352.80K derived: sum of 2 quarters · filed 2013-03-18 | $11.84M 10-K · filed 2013-03-18 | |||
| 2010-09-30 | $110.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $11.60M 10-Q · filed 2011-11-10 | ||||
| 2010-06-30 | $11.49M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |